I THE TOPY

NAVAL MEDICAL RESEARCH INSTITUTE



December 1989



AD-A219 411

A SENSITIVE AND SPECIFIC DNA PROBE FOR PLASMODIUM YOELII

J. R. Campbell

Naval Medical Research and Development Command Bethesda, Maryland 10814-5055

Department of the Navy Naval Medical Command Washington, DC 20372-5210



Approved for public release; distribution is unlimited

NOTICES

The opinions and assertions contained herein are the private ones of the writer and are not to be construed as efficial or reflecting the views of the naval service at large.

When U.S. Government drawings, specifications, or other data are used for any purpose other than a definitely related Government procurement operation, the Government thereby incurs no responsibility nor any obligation whatsoever, and the fact that the Government may have formulated, furnished or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise, as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use, or sell any patented invention that may be any way be related thereto.

Please do not request copies of this report from the Naval Medical Research Institute. Additional copies may be purchased from:

N: 021 Technical Information Service 5285 Port Royal Road Springfield, Virginia 22161

Federal Government agencies and their contractors registered with the Defense Technical Information Center should direct requests for copies of this report to:

Defense Technical Information Center Cameron Station Alexandria, Virginia 22304-6145

TECHNICAL REVIEW AND APPROVAL

NMRI 89-107

The experiments reported herein were conducted according to the principles set forth in the current edition of the "Guide for the Care and Use of Laboratory Animals," Institute of Laboratory Animal Resources, National Research Councils

This technical report has been reviewed by the NMRI scientific and public affairs staff and is approved for publications. It is releasable to the National Technical Information Service where it will be available to the general public, including foreign nations.

LARRY W. LAUGHUN CAPT, MC, USN

Commanding Officer
Naval Medical Research Institute

UNCLASSIFIED

•	•		_			_			_	_		_	_		
C	c /	-1	10		~			r			17.7				DAGE
2	۲,			I I T	C.L	.,,,,	. 3	18			IO N	ιu	•	INK	PAGE

1a. REPORT SECURITY CLASSIFICATION UNCL 2a. SECURITY CLASSIFICATION AUTHORITY 2b. DECLASSIFICATION / DOWNGRADING SCHEDULE 4. PERFORMING ORGANIZATION REPORT NUMBER(S) NMR1 89-107 5a. NAME OF PERFORMING ORGANIZATION Naval Medical Research Institute 6c. ADDRESS (City, State, and ZIP Code) 8901 Wisconsin Avenue Bethesda, MD 20814-5055 8b. OFFICE SYMBOL (If applicable) 8c. ADDRESS (City, State, and ZIP Code) 8901 Wisconsin Avenue Bethesda, MD 20814-5049 8c. ADDRESS (City, State, and ZIP Code) 8901 Wisconsin Avenue Bethesda, MD 20814-5049 8c. ADDRESS (City, State, and ZIP Code) 8901 Wisconsin Avenue Bethesda, MD 10814-5044 8c. ADDRESS (City, State, and ZIP Code) 8901 Wisconsin Avenue Bethesda, MD 10814-5044 8c. ADDRESS (City, State, and ZIP Code) 8901 Wisconsin Avenue Bethesda, MD 10814-5044 8c. ADDRESS (City, State, and ZIP Code) 8901 Wisconsin Avenue Bethesda, MD 10814-5044			REPORT DOCU	MENTATION	PAGE	*			
3. OSTRIBUTION AVAILABILITY OF REPORT 1. OSTRIBUTION AVAILABILITY OF RESTRICT 1. OSTRIBUTION AVA	1a. REPORT SECURITY CLASSIFICATION	ON							
Approved for public release; distribution is unlimited 4 PERFORMING ORGANIZATION REPORT NUMBER(S) NMRI 89-107 5. NAME OF PERFORMING ORGANIZATION 6b. OFFICE SYMBOL 7a. NAME OF MONITORING ORGANIZATION NAVAI Medical Command Naval Medical Research 6 Development Command Naval Medical Research 7 Development Command Naval Medical Research 8 Development Command Naval Medical Research 9 PROCUREMENT INSTRUMENT INSTRUME									
A PERFORMING ORGANIZATION REPORT NUMBER(S) S. MONITORING ORGANIZATION REPORT NUMBER(S)	Za. SECURITY CLASSIFICATION AUTH	ORITY		Approved for public release;					
So. NAME OF PERFORMING ORGANIZATION Naval Medical Research (if applicable) Institute 6c. ADDRESS (Ciry, Stare, and ZIP Code) 3901 Wisconsin Avenue Bethesda, MD 20814-5055 8a. NAME OF FUNDING/SPONSORING ORGANIZATION Naval Medical Research & Development Comman 8c. ADDRESS (Ciry, Stare, and ZIP Code) 0000 Nisconsin Avenue Bethesda, MD 10814-5054 8a. ADDRESS (Ciry, Stare, and ZIP Code) 0000 Nisconsin Avenue Bethesda, MD 10814-5044 8c. ADDRESS (Ciry, Stare, and ZIP Code) 0000 Nisconsin Avenue Bethesda, MD 10814-5044 8c. ADDRESS (Ciry, Stare, and ZIP Code) 10. SOURCE OF FUNDING NUMBERS 901 Wisconsin Avenue Bethesda, MD 10814-5044 8c. ADDRESS (Ciry, Stare, and ZIP Code) 8901 Wisconsin Avenue Bethesda, MD 10814-5044 11. ITILE (Include Security Classification) A Sensitive and Specific DNA Probe for Plasmodium yoelii 12. PERSONAL AUTHORIS) J. R. Campbell 13a, TYPE OF REPORT Technical Report 15b. THE COVERED FROM 1987 To 1989 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT Technical Report 16consider on reverse if necessary and identify by block number) 17. COSATI CODES FIELD GROUP SUB-GROUP 18. SUBJECT TERMS (Commove on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block	26. DECLASSIFICATION / DOWNGRAD	ING SCHEDE	. c						
SS. NAME OF PERFORMING ORGANIZATION Naval Medical Research Institute 6c. ADDRESS (Gry, State, and ZIP Code) 8901 Wisconsin Avenue Bethesda, MD 20814-5055 8a. NAME OF FUNDING/SPONSORING ORGANIZATION Naval Medical Research & Development Commane 8c. ADDRESS (Gry, State, and ZIP Code) 8901 Wisconsin Avenue 8c. ADDRESS (Gry, State, and ZIP Code) 8c. ADDRESS (Gry, State	4. PERFORMING ORGANIZATION REP	ORT NUMBE	R(S)	5. MONITORING	ORGANIZATION F	REPORT NUM	ER(S)		
Naval Medical Research Institute 6c. AppRess (Gry, State, and ZIP Code) 8901 Wisconsin Avenue Bethesda, MD 20814-5055 8a. NAME OF FUNDING/SPONSORING ORGANIZATION Naval Medical Research & Development Comman 8b. OFFICE SYMBOL (If applicable) 8a. NAME OF FUNDING/SPONSORING ORGANIZATION Naval Medical Research & Development Comman 8c. ADDRESS (City, State, and ZIP Code) Bana NAME OF FUNDING/SPONSORING ORGANIZATION Naval Medical Research & Development Comman 8c. ADDRESS (City, State, and ZIP Code) Bana NAME OF FUNDING (It have been been been been been been been be	NMRI 89-107								
The Address (Cry, State, and ZIP Code) Sethersday, MD 20814-5055	6a. NAME OF PERFORMING ORGANI	ZATION							
Bethesda, MD 20814-5055 Ba. NAME OF FUNDING/SPONSORING ORGANIZATION Naval Medical Research & Development Comman Research & Development Comman Bethesday (if applicable) Research & Development (if application) Research & Development (if application) Research & Development (if application) Research & Development (if applicable) Research & Development (if application) Research & PROGRAM (if ap		cn	(IT applicable)	Nava	Medical Co	mmand			
Bethesda, MD 20814-5055 Ba. NAME OF FUNDING (SPONSORING ORGANIZATION Naval Medical Research & Development Comman) Research & Development Comman Be. ADDRESS (City, State, and ZIP Code) 8901 Wisconsin Avenue Bethesda, MD 10814-5044 Bethesda, MD 10814-5044 Bethesda, MD 10814-5044 A Sensitive and Specific DNA Probe for Plasmodium yoelii 17. TITLE (Include Security Classification) A Sensitive and Specific DNA Probe for Plasmodium yoelii 18. TYPE OF REPORT Technical Report FROM 1987 To 1989 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) We have produced a DNA probe, designated pJC104, for the sensitive and specific identification of Plasmodium yoelii. The probe incorporates the major DNA repeat of parasite and has a sensitivity that exceeds that of all conventional methods of malar diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive transfer of immune cells, infusion of bio-active substances and immunization with subunit vaccian now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT A NAME OF FUNDING NUMBER 19. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER 10. SOURCE OF FUNDING NUMBERS	6c. ADDRESS (City, State, and ZIP Coo	de)							
BB. NAME OF FUNDING/SPONSORING ORGANIZATION Naval Medical Research & Development Commany BB. ADDRESS (City, State, and ZIP Code) Bethesda, MD 10814-5044 Bethesda, MD 10814-5044 TITLE (Include Security Classification) A Sensitive and Specific DNA Probe for Plasmodium yoelii 12. PERSONAL AUTHORIS) J. R. Campbell 13a. TYPE OF REPORT FROM 1987 To 1989 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT Technical Report FROM 1987 To 1989 16. SUPPLEMENTARY NOTATION 17. COSATI CODES FIELD GROUP SUB-GROUP 18. ABSTRACT (Continue on reverse if necessary and dentify by block number) We have produced a DNA probe, designated pJC104, for the sensitive and specific identification of Plasmodium yoelii. The probe incorporates the major DNA repeat of parasite and has a sensitivity that exceeds that of all conventional methods of malar diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive tran of immune cells, infusion of bio-active substances and immunization with subunit vacc can now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT DIC USERS 21. ABSTRACT SECURITY CLASSIFICATION 121. ABSTRACT SECURITY CLASSIFICATION 122. DISTRIBUTION/AVAILABILITY OF ABSTRACT DIC USERS 121. ABSTRACT SECURITY CLASSIFICATION 122. NAME OF REPORT INTERVENCE AND COMPANIANCE OF APER COMPANIANCE 122. NAME OF FEDONS INTERVENCENCE APER COMPANIANCE 123. NAME OF FEDONS INTERVENCENCE APER COMPANIANCE 124. NAME OF FEDONS INTERVENCENCE 15. SUBJECT TERMS (Continue on reverse if recessary and dentify by block number) 16. SUBJECT TERMS (Continue on reverse if recessary and dentify by block number) 17. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if recessary and dentify by block number) 18. DATE OF REPORT TO TAKE TO TAKE TO TAKE TO TAKE TO T									
ORGANIZATION Naval Medical Research & Development Comman 8c. ADDRESS (City, State, and ZIP Code) 8901 Wisconsin Avenue Bethesda, MD 10814-5044 Bethesda, MD 10814-5044 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 6277ØA 3M16277Ø A87Ø. AN DA317: 11. ITLE (Include Security Classification) A Sensitive and Specific DNA Probe for Plasmodium yoelii 12. FERSONAL AUTHOR(S) J. R. Campbell 13a. TYPE OF REPORT Technical Repo	bethesda, MU 20014-5	U55		Washi	ington, DC 2	0372-5120)		
Research & Development Comman Be. ADDRESS (City, State, and ZIP Code) 8901 Wiscons in Avenue Bethesda, MD 10814-5044 Bethesda, MD 10814-5044 11 ITTLE (Include Security Classification) A Sensitive and Specific DNA Probe for Plasmodium yoelii 12. PERSONAL AUTHOR(S) J. R. Campbell 13a. TYPE OF REPORT Technical Report FROM 1987 To 1989 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT Technical Report FROM 1987 To 1989 16. SUPPLEMENTARY NOTATION 17. COSATI CODES FIELD GROUP SUB-GROUP 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT X21. NAME OF REPORT (TERMS (Continue on reverse if necessary and identify by block number) 21. ABSTRACT SECURITY CLASSIFICATION 19. DISTRIBUTION/AVAILABILITY OF ABSTRACT 19. DITC USERS 21. ABSTRACT SECURITY CLASSIFICATION 19. DITC USERS 21. ABSTRACT SECURITY CLASSIFICATION 19. DITC USERS 21. ABSTRACT SECURITY CLASSIFICATION 19. DITC USERS 22. DATE OF REPORT (TERMS (CONTINUE ON PROPERTION CONTINUE ON PROPERTION CONTINUE ON PROPERTION CONTINUE ON PROPERTION CONTINUE ON PROPE				9. PROCUREMEN	NT INSTRUMENT IC	DENTIFICATIO	N NUMBER		
88. ADDRESS (City, State, and ZIP Code) 8901 Wiscons in Avenue Bethesda, MD 10814-5044 Bethesda, MD 10814-5044 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO.	,								
Bethesda, MD 10814-5044 ELEMENT NO. 6277 ØA 3M16277 Ø A87 Ø. AN ACCESSION A87 Ø. AN ACCESSION A87 Ø. AN AND 10817	8c. ADDRESS (City, State, and ZIP Cod	ie)	<u> </u>	10. SOURCE OF	FUNDING NUMBE	RS			
11. TITLE (Include Security Classification) A Sensitive and Specific DNA Probe for Plasmodium yoelii 12. PERSONAL AUTHOR(S) J. R. Campbell 13a. TYPE OF REPORT 13b. TIME COVERED 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT 15. TO 1989 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT 16. SUPPLEMENTARY NOTATION 16. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 17. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necess	-	_				TASK /	WORK UNIT		
A Sensitive and Specific DNA Probe for Plasmodium yoelii 12. PERSONAL AUTHOR(S) J. R. Campbell 13a. TYPE OF REPORT 13b. TIME COVERED 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT Technical Report FROM 1987 To 1989 890606 16. SUPPLEMENTARY NOTATION 17. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Plasmodium yoelii DNA probe, malaria diagnosis vaccine screening (Comparable) Plasmodium yoelii DNA probe, malaria diagnosis vaccine screening (Comparable) Plasmodium yoelii The probe incorporates the major DNA repeat of parasite and has a sensitivity that exceeds that of all conventional methods of malar diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive transof immune cells, infusion of bio-active substances and immunization with subunit vaccine development program Specifically Plasmodium yoelii SAME AS RPT DTIC USERS DTIC USERS Plasmodium yoelii	betnesda, MU 10014-50	044							
A Sensitive and Specific DNA Probe for Plasmodium yoelii 12. PERSONAL AUTHOR(S) J. R. Campbell 13a. TYPE OF REPORT Technical Report Technical Report Technical Report Technical Report 15. SUPPLEMENTARY NOTATION 17. COSATI CODES FIELD GROUP SUB-GROUP Teled GROUP SUB-GROUP 18. SUBJECT TERMS (Continue on reverse if recessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) We have produced a DNA probe, designated pJC104, for the sensitive and specific identification of Plasmodium yoelii. The probe incorporates the major DNA repeat of parasite and has a sensitivity that exceeds that of all conventional methods of malar diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive trans of immune cells, infusion of bio-active substances and immunization with subunit vacc can now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT ZUNCLASSIFIED/INJUNIALABILITY OF ABSTRACT ZUNCLASSIFIED/INJUNIALABILITY OF ABSTRACT DDIC USERS 21. ABSTRACT SECURITY CLASSIFICATION Unclassified 22. NAME OF RESPONSIBLE INDIVIDUAL 22. NAME OF RESPONSIBLE INDIVIDUAL	11. TITLE (Include Security Classificat	tion)		<u> </u>		<u> </u>			
13b. TIME COVERED FROM 1987 TO 1989 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT 890606 16. SUPPLEMENTARY NOTATION 17. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) We have produced a DNA probe, designated pJC104, for the sensitive and specific identification of Plasmodium yoelii. The probe incorporates the major DNA repeat of parasite and has a sensitivity that exceeds that of all conventional methods of malar diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive trans of immune cells, infusion of bio-active substances and immunization with subunit vacc can now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT DIC UNCLASSIFICATION Unclassified 21. ABSTRACT SECURITY CLASSIFICATION Unclassified	A Sensitive and Spe	ecific D	NA Probe for <u>Pla</u>	smodium yoe	lii				
13b. TIME COVERED Technical Report FROM 1987 TO 1989 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT Technical Report FROM 1987 TO 1989 16. SUPPLEMENTARY NOTATION 17. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 17. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identify by block number) 19. ABSTRACT (Continue on reverse if necessary and identif	12 PERSONAL AUTHOR(S)	C 1 1	7		 				
Technical Report FROM 1987 To 1989 890606 16. SUPPLEMENTARY NOTATION 17. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if recessary and identify by block number) FIELD GROUP SUB-GROUP SUB-GROUP Plasmodium yoelii malaria diagnosis DNA probe vaccine screening Vaccine scree	J. R.	Campbel	 						
18. SUBJECT TERMS (Continue on reverse if recessary and identify by block number) FIELD GROUP SUB-GROUP Plasmodium yoelii malaria diagnosis NA probe; We have produced a DNA probe, designated pJC104, for the sensitive and specific identification of Plasmodium yoelii. The probe incorporates the major DNA repeat of parasite and has a sensitivity that exceeds that of all conventional methods of malar diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive transfer immune cells, infusion of bio-active substances and immunization with subunit vaccine can now be reliably measured.			OVERED		ORT (Year, Month,	Day) 15. P	AGE COUNT		
18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Plasmodium yoelii malaria diagnosis; 19. ABSTRACT (Continue on reverse if necessary and identify by block number) We have produced a DNA probe, designated pJC104, for the sensitive and specific identification of Plasmodium yoelii. The probe incorporates the major DNA repeat of parasite and has a sensitivity that exceeds that of all conventional methods of malar diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive trans of immune cells, infusion of bio-active substances and immunization with subunit vacc can now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT MUNCLASSIFIEDAUNLIMITED SAME AS RPT DIC USERS Unclassified 21. ABSTRACT SECURITY CLASSIFICATION Unclassified 22. ANAME OF RESPONSIBLE INDIVIDUAL 22. NAME OF RESPONSIBLE INDIVIDUAL 22. NAME OF RESPONSIBLE INDIVIDUAL		PROM 13	10 1 303	030000	. · · · · · · · · · · · · · · · · · · ·	1			
Plasmodium yoelii malaria diagnosis, vaccine screening vaccine scr									
malaria diagnosis, vaccine screening. 19. ABSTRACT (Continue on reverse if necessary and identify by block number) We have produced a DNA probe, designated pJC104, for the sensitive and specific identification of Plasmodium yoelii. The probe incorporates the major DNA repeat of parasite and has a sensitivity that exceeds that of all conventional methods of malar diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive trans of immune cells, infusion of bio-active substances and immunization with subunit vacc can now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT ZUNCLASSIFIEDAUNLIMITED SAME AS RPT DTIC USERS 21. ABSTRACT SECURITY CLASSIFICATION Unclassified 22. NAME OF RESPONSIBLE INDIVIDUAL	17. COSATI CODES		18. SUBJECT TERMS (Continue on rever	se if necessary an	d identify by	block number)		
malaria diagnosis, vaccine screening. 19. ABSTRACT (Continue on reverse if necessary and identify by block number) We have produced a DNA probe, designated pJC104, for the sensitive and specific identification of Plasmodium yoelii. The probe incorporates the major DNA repeat of parasite and has a sensitivity that exceeds that of all conventional methods of malar diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive trans of immune cells, infusion of bio-active substances and immunization with subunit vacc can now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT ZUNCLASSIFIEDAUNLIMITED SAME AS RPT DTIC USERS 21. ABSTRACT SECURITY CLASSIFICATION Unclassified 22. NAME OF RESPONSIBLE INDIVIDUAL	FIELD GROUP SUB	-GROUP] [∭] Plasmodium yo	oelii DN	iA probe,		1.		
19. ABSTRACT (Continue on reverse if necessary and identify by block number) We have produced a DNA probe, designated pJC104, for the sensitive and specific identification of Plasmodium yoelii. The probe incorporates the major DNA repeat of parasite and has a sensitivity that exceeds that of all conventional methods of malar diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive transfer immune cells, infusion of bio-active substances and immunization with subunit vaccion now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT ZII. ABSTRACT SECURITY CLASSIFICATION Unclassified 21. ABSTRACT SECURITY CLASSIFICATION Unclassified 22. NAME OF RESPONSIBLE INDIVIDUAL			malaria diagr	nosis y	iccine scree	ning $ullet(\mathcal{E}_i)$	z) 、		
identification of Plasmodium yoelii. The probe incorporates the major DNA repeat of parasite and has a sensitivity that exceeds that of all conventional methods of malar diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive trans of immune cells, infusion of bio-active substances and immunization with subunit vacc can now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT CAN DISTRIBUTION DISTRIBUTION DIST	19. ABSTRACT (Continue on reverse	if necessary	and identify by block r						
parasite and has a sensitivity that exceeds that of all conventional methods of malar diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive transfer of immune cells, infusion of bio-active substances and immunization with subunit vaccion now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT ZUNCLASSIFIED/UNLIMITED									
diagnosis. The probe represents a major breakthrough for the Navy's malaria vaccine development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive transfer of immune cells, infusion of bio-active substances and immunization with subunit vaccion now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT ZI. ABSTRACT SECURITY CLASSIFICATION Unclassified 21. ABSTRACT SECURITY CLASSIFICATION Unclassified 22. NAME OF RESPONSIBLE INDIVIDUAL 22. NAME OF RESPONSIBLE INDIVIDUAL	identification of Pla	a smodium	yoelii. The pr	robe incorpo	rates the m	ajor DNA	repeat of the		
development program, as it provides a means for quantifying the protective effects of experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive transfer of immune cells, infusion of bio-active substances and immunization with subunit vace can now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT MUNCLASSIFIED/UNLIMITED									
experimental immune interventions in the mouse P. yoelii system. Specifically, protection against challenge infection by passive transfer of antibody, adoptive transfer of immune cells, infusion of bio-active substances and immunization with subunit vaccion now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT AUNCLASSIFIED/UNLIMITED									
protection against challenge infection by passive transfer of antibody, adoptive transfer of immune cells, infusion of bio-active substances and immunization with subunit vaccion now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT MUNICLASSIFIED/UNLIMITED									
of immune cells, infusion of bio-active substances and immunization with subunit vaccion now be reliably measured. 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT MUNICLASSIFIED/UNLIMITED SAME AS RPT DTIC USERS 21. ABSTRACT SECURITY CLASSIFICATION Unclassified Unclassified 22. NAME OF RESPONSIBLE INDIVIDUAL 22. NAME OF RESPONSIBLE INDIVIDUAL	protection against cl	hallenge	infection by pa	ssive trans	fer of anti	bodv. ado	ptive transfe		
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT \$\times \text{Unclassification} \text{Same as RPT} \text{Dtic users} \text{Unclassification} \text{21. ABSTRACT SECURITY CLASSIFICATION} \text{Unclassification} \text{223. NAME OF RESPONSIBLE INDIVIDUAL} \text{224. NAME OF RESPONSIBLE INDIVIDUAL} \text{225. CFFCE SYMBOL}									
MUNCLASSIFIED/UNLIMITED SAME AS RPT. DTIC USERS Unclassified 228. NAME OF RESPONSIBLE INDIVIDUAL 228. TELEPHONE (MICHAEL Area Code) 220. OFFICE SYMBOL	can now be reliably n	measured	• · · · · · · · · · · · · · · · · · · ·						
MUNCLASSIFIED/UNLIMITED ☐ SAME AS RPT. ☐ DTIC USERS Unclassified 22a. NAME OF RESPONSIBLE INDIVIDUAL 22b. TELEPHONE (Include Area Code) 22c. OFFICE SYMBOL									
MUNCLASSIFIED/UNLIMITED ☐ SAME AS RPT. ☐ DTIC USERS Unclassified 22a. NAME OF RESPONSIBLE INDIVIDUAL 22b. TELEPHONE (Include Area Code) 22c. OFFICE SYMBOL									
MUNCLASSIFIED/UNLIMITED SAME AS RPT. DTIC USERS Unclassified 228. NAME OF RESPONSIBLE INDIVIDUAL 228. TELEPHONE (MICHAEL Area Code) 220. OFFICE SYMBOL									
228. NAME OF RESPONSIBLE INDIVIDUAL [23b. TELEPHONE (Include Area Code) 23c. OFFICE SYMBOL						CATION			
Regina E. Hunt, Command Editor (202) 295-0198 SD/RSD/NAR1	22a. NAME OF RESPONSIBLE INDIVID	DUAL		226. TELEPHONE	Include Area Code	1) 356' OHIO	1 SYMBOL		
ST ADS edition may be used until exhausted	Regina E. Hunt, Commi				0198	SU/RSD	MARI		

Table of Contents

Materials and Methods	
Results	3
Discussion	4
References	5
Acknowledgements	6

Acces	ssion F	Or			
NTIS	GRA&I				
DTIC	TAB		ñ		
Unanı	pesuror		ñ		
Justi	ficatio	n			
·					
Ву					
Distr	ibution	1/			
Avai	labilit	y Co	des		
	Avail &	o\bai	r	_	
Otst .	Speci	al		- 1	
1.	1			- 1	
0,				- }	
r	i i			- 1	
•				- 1	



Plasmodium yoelii, a parasite causing murine malaria, has found many applications as a model system for studying human malaria. Currently, malaria vaccine development efforts are focused on interrupting the development of the parasite in the host's liver. Various biochemical and immunological interventions have been developed to kill or slow the development of the parasite at this stage, however, quantification of the effects of these treatments has been problematic. Current methods for quantifying the inhibitory effects of immunization protocols on liver stage development have been largely inferential, based on reduction in blood parasitemias, or have relied on examination of stained tissue sections.

The objective of the studies reported in this paper was to produce a DNA probe that could be used for the identification and quantification of *P. yoelii* infections in infected blood, in liver tissue sections *in situ*, and in total DNA extracts of infected liver.

MATERIALS AND METHODS

Production and purification of Plasmodium yoelii-infected erythrocytes

Plasmodium yoelii (I7X NL strain) was used to infect 40 Balb/c mice. When parasitemias reached 10-20%, mice were bled retro-orbitally into Na-heparin. The pooled blood was layered over an equal volume of acid washed glass beads (Sigma, St. Louis, Missouri) in 50 cc syringe barrels. Glass beads were pre-wetted with IX SSC (150 mM NaCl, 15 nM Na citrate, pH 7.0), and the blood was washed through the column with additional IX SSC. The blood eluate was then layered over a 2X volume of CF-II cellulose (Whatman, Hillsboro, Oregon) lightly packed into 50 cc syringe barrels. The CF-II was thoroughly pre-wetted with IX SSC, and additional IX SSC was used to elute the blood until the cellulose cleared to pale pink.

The diluted blood was centrifuged 10 min at 1500 rpm and resuspended to its original volume in IX SSC. The blood was then layered over lymphocyte separation medium (LSM - Organon, Durham, North Carolina) and spun at 2500 rpm for 20 min. The majority of infected RBCs banded at the LSM/plasma interface, and this band was harvested, washed twice in IX SSC and used for further processing.

Isolation and purification of parasite DNA

The LSM band, containing infected RBC and essentially free of contaminating mouse WBC, was resuspended in 30 ml of IX SSC containing 1% saponin and placed on ice for 15 min. The preparation was spun at 8000 rpm for 10 min, the supernate was discarded, and the saponin lysis was reneated twice, until the supernate was clear. The pellet, containing free parasites and erythrocyte ghosts, was suspended in 4 ml of a 4% solution of sarkosyl containing 1 mg/ml proteinase K. The preparation was incubated at 37 C for 1 hr and solid CsCl was added to a final concentration of 1 gm/ml. Hoescht dye was added to a final concentration of 1 ug/ml, and the preparation was spun at 35, 000 rpm for 48 hr in a Beckman 50Ti rotor.

After centrifugation the dense, uppermost band was recovered, extracted with isopropanol and dialyzed 1: 10⁸ against IX TE (10 mM Tris, 1 mM EDTA, pH7.5).

Production of plasmid library of P. voelii DNA

Purified *P. yoelii* DNA was cut with Hind III, ligated into Hind III cut plasmid pBR322 according to standard methods (1), and plated onto Luria broth (LB) agar containing 50 ug/ml ampicillin (amp). Ampicillin resistant colonies were transferred to duplicate LB plates containing amp or tetracycline (tet - 28 ug/ml). Ampicillin resistant, tet sensitive colonies were then transferred to duplicate LB amp plates. The following day, colonies were lifted onto nitrocellulose filters, processed according to Davis et al. (2₃₂) (hybridized with either nick-translated ³²P-P. yoelii DNA or ³²P-mouse DNA. Colonies that hybridized strongly with *P. yoelii* DNA but failed to hybridize with mouse DNA were selected for further analysis. Selection and characterization of *P. yoelii* DNA clones

From the pBR322 library of *P. yoelii* DNA fragments 5 clones were selected for further analysis. Cross-hybridization of these clones with each other suggested that they shared a common sequence, and the strength of the hybridization signal to *P. yoelii* genomic DNA suggested that this sequence encoded a major repeated element. One clone, pJClO4, gave an exceptionally strong signal and was selected as a candidate probe. Restriction enzyme analysis of pJClO4 revealed an insert of 3.16 kb, containing sites for the restriction enzymes Cla I, Sca I and Ssp I (Fig. 1).


Applications of the probe for detecting P. yoelii DNA

To determine the absolute sensitivity of the probe, dilutions of *P. yoelii* DNA (1 pg - 1 ng) were applied to nitrocellulose in 50 ul volumes, using a slot blot apparatus (Minifold II, Schleicher & Schuell, Keene, New Hampshire). Nitrocellulose blots were processed by placing them over filter papers saturated with reagents as follows: 0.5 N NaOH, 10 min; IM Tris, pH 7.0, 2 min (twice); IM Tris, pH 7.0, 1.5 M NaCl, 10 min. The blots were then dried and baked at 80 C for 2 hr. Processed blots were hybridized against ³²P-pJClO4. The probe was also hybridized against Southern blots of Hind III digested *P. yoelii* genomic DNA to determine the banding pattern.

To determine the sensitivity of the probe for detecting *P. yoelii* DNA in the presence of host DNA, dilutions of *P. yoelii* DNA were made into a solution of mouse DNA to produce samples containing *P. yoelii*:mouse DNA in ratios of 1:10⁷ to 1:10³. Total DNA concentration of the samples was held constant and 1 ug of each was applied to an agarose gel. After electrophoresis, the samples were transferred to nitrocellulose and hybridized against ³²P-pJClO4. Alternatively, *P. yoelii* DNA was diluted into 20 ug of mouse DNA, in the same ratios as above, and applied in 100 ul volumes to 1 inch nitrocellulose squares. Nitrocellulose was processed as for slot blots, and then hybridized against the probe.

To determine the sensitivity of the probe for detecting erythrocytic stages of *P. yoelii*, mouse blood infected with *P. yoelii* was diluted with uninfected mouse blood in eppendorf tubes to produce parasitemias ranging from 1.0% - .0001%. Twenty ul of each dilution was spotted onto nitrocellulose and air dried. Spots were then processed according to Mucenski et al., (3) and hybridized against ³²P-pJClO4.

RESTRICTION MAP OF PJC104 INSERT



insert = 3160 bp

FIGURE 1

To determine if pJClO4 could be used for detecting liver stages of *P. yoelii*, Wistar rat hepatocytes were grown in microculture on Lab Tek chamber slides (Nunc, Naperville, Illinois), and infected with sporozoites of *P. yoelii* (I7X NL strain). Duplicate cultures containing IO⁵-hepatocytes were prepared and stained with monoclonal antibody NYSI (1/100 dilution) against the circumsporozoite protein of *P. yoelii* to confirm and quantitate liver cell infections. Uninfected liver cell cultures were maintained as negative controls.

Cell cultures were transferred and lysed by inverting the slides onto nitrocellulose in petri dishes, over filter paper saturated with IM Tris, pH 7.0, containing 10% sarkosyl and 1 mg/ml proteinase K. Petri dishes were covered, sealed with parafilm and held for 2-24 hr at 37°C. The nitrocellulose was then processed as for slot blot preparations and baked at 80°C in vacuo for 2 hr to fix the DNA to the paper. Duplicate samples were prepared as described above and hybridized to ³²P-pJClO4. One set of the hybridized cell transfers was used for autoradiography, while the duplicate set was counted in 5 ml of scintillation fluid in a Beckman LS 9000 scintillation counter.

Additionally, detection of liver stage parasites was studied by *in situ* hybridization. Ten micron-thick cryosections of *P. yoelii* infected mouse liver on glass microscope slides were processed according to the method of Lum (4) and hybridized with ³²P-pJClO4. Tissue sections on the slides were washed, dipped in photographic emulsion (NTB2, Kodak, Rochester, New York), and held at 4 C in the dark for periods ranging from 12 hr to 1 wk. Slides were developed, counterstained with hematoxylin and eosin and examined at 400 or IOOOX in a compound microscope for exposure of the emulsion at the locations of parasites.

To determine the specificity of pJClO4 for *P. yoelii* DNA, dilutions of *P. falciparum*, *P. vivax*, *P. yoelii*, *P. berghei*, human, chimpanzee and mouse DNA were slot-blotted to nitrocellulose and hybridized with the probe.

RESULTS

Production/purification of P. voelii DNA

The purification procedure described above resulted in very high yields of exceptionally pure *P. yoelii* genomic DNA. As mentioned in Materials and Methods, the infected mouse RBCs were localized primarily in the LSM band. Interestingly, the same protocol applied to the purification of human malaria parasites (*P. falciparum*, *P. vivax*, *P. malariae* and *P. ovale*) from the blood of experimentally infected chimpanzees resulted in the localization of infected RBC in the erythrocyte pellet rather than the LSM band after centrifugation (J. Campbell, unpublished results - see NMRI technical report, June 1989).

Ultracentrifugation through CsCl resulted in two bands - an upper band of *P. yoelii* DNA and a lower, minor band of host (mouse) DNA.

Detection of P. voelii DNA using pJClO4

Using the nitrocellulose slot blot, pJClO4 detected a minimum of 1 pg of *P. yoelii* genomic DNA, equivalent to the DNA of 10 parasites. Southern blot analysis using the probe revealed a pattern of

multiple bands (Fig. 2) on Hind III digested *P. yoelii* genomic DNA. After agarose gel electrophoresis and Southern blotting, dilutions of *P. yoelii* DNA in mouse DNA were detected at a ratio of 1 ng *P. yoelii*:l ug mouse, ie, in the presence of a thousand-fold excess of host DNA. However, autoradiography of the diluted DNA applied directly to nitrocellulose allowed detection of parasite DNA in the presence of a IO⁵-fold excess of host DNA, after a 48 hr exposure.

Spots of mouse blood (20 ul) were detected by the probe with parasitemias as low as .001%, equivalent to 10⁴ parasites. In liver cell cultures transferred to nitrocellulose the probe successfully detected 29 schizonts/10⁵ cells and produced a visible signal after 18 hr exposure on the autoradiograph. These results were corroborated by scintillation counter results which revealed counts in the infected samples more than 4 SD above negative (uninfected) control samples. Tissue sections probed *in situ* with pJClO4 revealed specific, focal hybridization of the probe to liver stage parasites, with a distinct autoradiographic signal by 16 hr, however background was high. Experiments to reduce background and increase the signal:noise ratio are continuing.

With the specificity of pJClO4 for purified *P. yoelii* DNA taken to be 100%, cross-reactivity of less than 1% to *P. berghei* DNA was observed. The probe failed completely to hybridize to purified DNA from *P. falciparum*, *P. vivax*, human, chimpanzee or mouse.

DISCUSSION

Data presented in this paper indicate that pJClO4 contains a sequence that is homologous to a major repeated element in *P. yoelii* DNA. The sensitivity of this probe for detecting blood infections equals or exceeds that available by examination of Giemsa stained smears. This probe provides the first sensitive and reproducible method for diagnosing and quantifying liver stage infections in the mouse - *P. yoelii* model system.

Development of probe pJClO4 has taken two years, and represents a major breakthrough for the Navy's malaria vaccine development program. Up to this time the program has been handicapped by the lack of a sensitive, reproducible method for quantifying the effects of experimental immune interventions in its *P. yoelii* animal model system. The specificity and the high sensitivity of this probe will allow the effects on protection of such treatments as passive transfer of hyper-immune sera or monoclonal antibodies, adoptive transfer of immune cells or infusions of bio-active substances (eg., ganMa interferon) to be quantified. Additionally, the effects of ablating portions of the immune system (T-cell subsets, Ig-producing cells) on protection against infection can be studied, to clarify host-parasite relationships. Last, but not least, experimental vaccines (whole natural antigens, recombinant proteins, subunit peptides and anti-idiotype antibodies) can be tested in the murine system and their effects on subsequent challenge infection can be measured with this probe.




FIGURE 2 Southern blot of Hind III digested \underline{P} . yoelii DNA hybridized to pJC104

REFERENCES

- 1. Maniatis, T., Fritsch, E.F., Sambrook, J. Molecular Cloning, Cold Spring Harbor, New York, 1982.
- 2. Davis, R.W., Botstein, D., Roth, J.R. Advanced Bacterial Genetics, Cold Spring Harbor, New York, 1980.
- 3. Mucenski, C.M. et al. 1986. Evaluation of a synthetic oligonucleotide probe for diagnosis of *Plasmodium falciparum* infections. AJTMH 35: 912-920.
- 4. Lum, J.B. 1986. Visualization of mRNA transcription of specific genes in human cells and tissues using *in situ* hybridization. Biotechniques 4: 32-39.

ACKNOWLEDGEMENTS

This research was supported by the Naval Medical Research Institute, work unit 3M162770A870AN121. The opinions and assertions contained herein are the private ones of the author and are not to be construed as official or as reflecting the views of the Navy Department or the naval service at large. The experiments reported herein were conducted according to the principles set forth in the Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, National Research Council, DHHS Publication 86-23, (1985). We thank M. Sedegah for *Plasmodium yoelii* parasites, S. Mellouk for hepatocyte cultures and D. Cautivar for technical support.